Fucosidosis is a rare autosomal recessive lysosomal storage disorder characterized by progressive psychomotor retardation, facial dysmorphism, deafness, angiokeratoma, neurologic signs, moderate hepatomegaly, and dysostosis multiplex. Fucosidosis has been graded into two major types, type 1 (severe) and type 2 (moderate). Age of onset for type 1 ranges between 3 and 18 months and is differentiated through rapid psychomotor regression and severe neurologic deterioration commencing 6 months of age, elevated sweat chloride, and fatality within the first decade of life. Type 2 has slower progression and is differentiated through milder psychomotor retardation and neurologic symptoms, the growth of angiokeratoma corporis diffusum, normal sweat salinity, and extended survival. Fucosidosis originates due to alpha-L-fucosidase deficiency with a buildup of fucose in body tissues. Fucosidosis is treated through allogenic bone marrow transplantation; however, fewer than 10 cases worldwide have undergone this treatment.
Fucosidosis is caused due to mutations in the fucosidase, alpha-L-1, tissue (FUCA1) gene, which encodes alpha-L-fucosidase enzyme.